comparemela.com

Latest Breaking News On - ஜான்சன் புற்றுநோய் மையம் - Page 1 : comparemela.com

Eliminating RNA-binding protein improves survival in aggressive leukemia

Scientists find that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone UCLA Broad Stem Cell Research Center Dr. Dinesh Rao and his colleagues had previously identified the IGF2BP3 protein as a factor in driving the development of leukemia through its regulation of RNA messages. Denise Heady | July 28, 2021 Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer’s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center. The research, published today in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer s development

Removing RNA-binding protein in subtype of leukemia can help to slow the cancer s development Removing a protein that is often overexpressed in a rare and aggressive subtype of leukemia can help to slow the cancer s development and significantly increase the likelihood of survival, according to a study in mice led by scientists at the UCLA Jonsson Comprehensive Cancer Center. The research, published in the journal Leukemia, could aid in the development of targeted therapies for cancers that have high levels of the RNA-binding protein IGF2BP3 -; especially acute lymphoblastic and myeloid leukemias that are characterized by chromosomal rearrangements in the mixed lineage leukemia (MLL) gene.

Eliminating RNA-binding protein improves survival in aggressive leukemia

Eliminating RNA-binding protein improves survival in aggressive leukemia
scienceblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scienceblog.com Daily Mail and Mail on Sunday newspapers.

Tool helps predicts who will respond best to targeted prostate cancer therapy

New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows UCLA Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady | July 8, 2021 A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy. The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.